Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-09-06, Stock:ABBV, The news for the past five days is as follows:
2019-08-29: NEWS1: Big Pharma kills signature drug at center of $5.8 billion South S.F. deal.NEWS2: Health Care Sector Update for 08/29/2019: AZN, ABBV, IBIO.NEWS3: Health Care Sector Update for 08/29/2019: AZN, ABBV, IBIO.NEWS4: UPDATE 1-AbbVie abandons late-stage lung cancer asset Rova-T.NEWS5: AbbVie Discontinues Phase III Trial of Drug to Treat Small-Cell Lung Cancer.NEWS6: AbbVie is shutting down its troubled Rova-T R&D program.NEWS7: AbbVie terminates late-stage lung cancer trial.NEWS8: AbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program.
2019-08-30: NEWS1: Pharma Stock Roundup: JNJ's Opioid Lawsuit, Regulatory Nod for LLY, BMY, RHHBY Drugs.NEWS2: Pharma Stock Roundup: JNJ's Opioid Lawsuit, Regulatory Nod for LLY, BMY, RHHBY Drugs.NEWS3: AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails.NEWS4: AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails.NEWS5: Notable ETF Outflow Detected - IXJ, ABBV, LLY, CVS.NEWS6: Notable ETF Outflow Detected - IXJ, ABBV, LLY, CVS.NEWS7: AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails.NEWS8: Pharma Stock Roundup: JNJ's Opioid Lawsuit, Regulatory Nod for LLY, BMY, RHHBY Drugs.
2019-09-03: NEWS1: Why Bank of America Says Dividend Stocks are the Only Play Now.NEWS2: The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie.NEWS3: The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie.NEWS4: The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie.
2019-09-04: NEWS1: 3 Lessons From AbbVie's $5.8 Billion Blunder With Cancer Drug Rova-T.NEWS2: 3 Lessons From AbbVie's $5.8 Billion Blunder With Cancer Drug Rova-T.NEWS3: 3 Lessons From AbbVie&apos;s $5.8 Billion Blunder With Cancer Drug Rova-T.
2019-09-05: NEWS1: 3 Special Situations Gurus Are Buying.NEWS2: J&J's Stelara Gets Approval in EU for Ulcerative Colitis.NEWS3: J&J's Stelara Gets Approval in EU for Ulcerative Colitis.NEWS4: J&J's Stelara Gets Approval in EU for Ulcerative Colitis.NEWS5: 5 Dividend Aristocrats Where Analysts See Capital Gains.NEWS6: 5 Dividend Aristocrats Where Analysts See Capital Gains.NEWS7: Can Biosimilars Take On $198 Billion In Blockbuster Drug Sales?.

Answer: Rise